Overview

GUARDIAN (NCT04884802) Sub-study, Phenylephrine v. Norepinephrine

Status:
Enrolling by invitation
Trial end date:
2025-07-01
Target enrollment:
Participant gender:
Summary
Some patients participating in the underlying GUARDIAN trial (NCT04884802) will be additionally randomized to norepinephrine or phenylephrine infusion to maintain the designated target intraoperative mean arterial pressure.
Phase:
Phase 4
Details
Lead Sponsor:
The Cleveland Clinic
Treatments:
Norepinephrine
Oxymetazoline
Phenylephrine